文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

术中血液吸附与心脏手术后急性肾损伤:更新系统评价与试验序贯分析

Intraoperative hemoadsorption and cardiac surgery-associated acute kidney injury: an updated systematic review and meta-analysis with trial sequential analysis.
PubMed 文献 · Crit Care · 2026-07-24
一句话结论成人心脏手术术中血液吸附未显著降低CSA-AKI(RR 0.80,95%CI 0.63-1.03),证据质量极低且信息量不足,不能作为常规推荐。

该更新系统评价与Meta分析纳入15项RCT,其中9项(947例)报告CSA-AKI,比较成人心脏手术术中血液吸附与标准治疗。血液吸附未显著降低CSA-AKI(RR 0.80,95%CI 0.63-1.03,P=0.08,I2=40%,GRADE极低),各分期AKI与肾脏替代治疗均无显著差异,死亡等临床终点相当。仅IL-8总体下降(MD -18.23,95%CI -31.90至-4.56)。TSA提示所需信息量未达到,结论不能确定,需进一步大规模RCT。

要点

  • 成人心脏手术术中血液吸附对比标准治疗,CSA-AKI无显著下降:RR 0.80(95%CI 0.63-1.03,P=0.08),GRADE证据质量极低。
  • AKI各分期均无显著差异:Stage 1 RR 0.72(0.49-1.05)、Stage 2 RR 0.66(0.30-1.43)、Stage 3 RR 0.43(0.17-1.05)。
  • 肾脏替代治疗RR 0.52(95%CI 0.22-1.25,P=0.15),死亡与其他临床终点两组相当。
  • 探索性结局中仅IL-8总体下降(MD -18.23,95%CI -31.90至-4.56,P=0.009),不能作为床旁决策依据。
  • TSA提示所需信息量未达到,且结果对模型选择及两项研究(Diab 2022、Abou-Arab 2025)的纳入敏感,结论不稳健。

适用人群与场景

  • 纳入标准:成人、接受心脏手术、术中行血液吸附对比标准治疗的RCT;排除人群原文未提及。
  • 场景为心脏手术术中,非急诊或ICU床旁常规使用场景。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径或疗程;干预为术中血液吸附对比标准治疗。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:更新系统评价与Meta分析(PRISMA),检索至2025年2月8日,纳入15项RCT,其中9项报告CSA-AKI共947例。
  • 主要终点CSA-AKI:血液吸附组无显著降低,RR 0.80(95%CI 0.63-1.03,P=0.08,I2=40%,GRADE极低)。
  • 次要终点:AKI Stage 1/2/3及肾脏替代治疗均无显著差异;死亡与其他临床终点两组相当;仅IL-8总体下降(MD -18.23,95%CI -31.90至-4.56)。
  • 亚组分析按装置类型无显著交互;TSA提示所需信息量未达到。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与Meta分析;GRADE证据质量极低。
  • 局限:纳入研究样本量有限(CSA-AKI分析947例)、信息量不足(TSA未达所需信息量)、结果对模型选择及两项研究(Diab 2022、Abou-Arab 2025)的纳入敏感,原文未提及其他局限。

对床旁实践的改变

  • 不改变现行实践:现有极低质量证据不支持在成人心脏手术中常规使用术中血液吸附来预防CSA-AKI。
  • 适用人群为成人心脏手术患者;不适用于原文未提及的人群。
  • 常见陷阱:将IL-8下降或严重AKI的趋势性RR(如Stage 3 RR 0.43)误读为临床获益;TSA信息量不足,阴性结果不能等同于确证无效。

指南或共识出处

  • 原文未提及具体指南或共识名称;本研究注册号PROSPERO CRD420250651941。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Cardiac surgery-associated acute kidney injury (CSA-AKI) following cardiopulmonary bypass (CPB) remains a high-risk complication with limited effective management. Hemoadsorption is increasingly used as an adjunctive therapy due to its potent cytokines clearance in experimental settings, yet its clinical efficacy is debated. This study aimed to evaluate the effect of hemoadsorption versus standard care on CSA-AKI and other major outcomes in adult cardiac surgery patients.

METHODS: An updated systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted following PRISMA guidelines. PubMed, Medline, Embase, Web of Science, and the Cochrane Library were systematically searched from inception to 8 February 2025. Eligible RCTs enrolled adult patients undergoing cardiac surgery and compared intraoperative hemoadsorption with standard care, with reported outcomes including CSA-AKI and other major endpoints. Pooled estimates were synthesized using inverse-variance random-effects models, with heterogeneity quantified by I² statistics. Subgroup, sensitivity and trial sequential analyses (TSA) were further performed.

RESULTS: Fifteen RCTs were included, of which nine reported CSA-AKI (947 patients). Hemoadsorption was not associated with a statistically significant reduction in CSA-AKI (RR 0.80, 95% CI 0.63-1.03, P = 0.08, I2 = 40%, GRADE: very low). The finding was sensitive to model choice and the inclusion of two studies (Diab 2022 and Abou-Arab 2025). Subgroup analyses revealed no significant interaction by device type. TSA indicated that the required information size was not reached. No significant differences were observed for CSA-AKI Stage 1 (RR 0.72, 95% CI 0.49-1.05, P = 0.09, I2 = 16%), Stage 2 (RR 0.66, 95% CI 0.30-1.43, P = 0.29, I2 = 11%), Stage 3 (RR 0.43, 95% CI 0.17-1.05, P = 0.06, I2 = 0%), or renal replacement therapy (RR 0.52, 95% CI 0.22-1.25, P = 0.15, I2 = 0%). Mortality and other clinical endpoints were comparable between groups. Among exploratory outcomes, only an overall reduction in IL-8 was noted (MD -18.23, 95% CI -31.90 to -4.56, P = 0.009, I2 = 40%).

CONCLUSIONS: Intraoperative hemoadsorption did not significantly reduce CSA-AKI or improve clinical outcomes in adult cardiac surgery. Although trends favored severe AKI, very low certainty evidence and insufficient information preclude definitive conclusions, warranting further large-scale RCTs.

REGISTRATION: PROSPERO identifier CRD420250651941.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Liu M, Lin D, Zhou R, et al. Intraoperative hemoadsorption and cardiac surgery-associated acute kidney injury: an updated systematic review and meta-analysis with trial sequential analysis. Crit Care. 2026. PMID: 42498964. doi:10.1186/s13054-026-06099-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。